Guanfacine Extended-release Tablet, Extended Release
Product Images NDC 50090-6493

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Guanfacine Extended-release (NDC 50090-6493). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line graph comparing guanfacine plasma concentrations over 24 hours for extended-release and immediate-release formulations, both dosed at 1 mg once daily. The x-axis shows time in hours (0 to 24), and the y-axis shows guanfacine plasma concentration in ng/mL (0 to 4.0). The extended-release guanfacine is represented by a solid line with square markers, showing gradual concentration changes, while the immediate-release guanfacine is a dashed line with triangle markers, peaking earlier and higher.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A pharmacokinetic fold change chart showing the impact of various CYP3A4/5 inhibitors and inducers, as well as other drugs, on the Cmax and AUC of guanfacine extended-release. The chart includes data for ketoconazole, fluconazole, rifampin, efavirenz, oral methylphenidate, and lisdexamfetamine dimesylate, with fold change values and 90% confidence intervals relative to reference values.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A figure presenting fold change and 90% confidence intervals of pharmacokinetic parameters Cmax and AUC for oral methylphenidate and lisdexamfetamine dimesylate, showing change relative to a reference value of 1.0.*
FDA Label Image

Figure4.jpg (Figure4)

Figure4.jpg (Figure4)
A line chart showing treatment failure percentage over time in days for two groups: Placebo (solid line) and SPD503 (dashed line). The y-axis represents treatment failure percentage, ranging from 0% to 100%, and the x-axis represents time to treatment failure in days, from 0 to about 200 days. The chart indicates that treatment failure increases over time, with the Placebo group showing a higher failure rate compared to SPD503.*
FDA Label Image

Label Image (Lbl500906493)

Label Image (Lbl500906493)
Guanfacine extended-release 3 mg oral tablets in a bottle labeled by A-S Medication Solutions. The label indicates each tablet contains 3 mg guanfacine hydrochloride and includes storage instructions to keep between 68 to 77 degrees Fahrenheit, protected from moisture. The package contains 90 tablets with the NDC 50090-6493.*
FDA Label Image

Spd503-chemical-stucture (Spd503 Chemical Stucture)

Spd503-chemical-stucture (Spd503 Chemical Stucture)
Chemical structure of guanfacine hydrochloride showing the molecular arrangement of atoms, including chlorine (Cl) atoms and functional groups. The structure depicts the hydrochloride salt form of guanfacine.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.